(JYNT) The Joint - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US47973J1025
Chiropractic,Clinic,Franchise,Wellness
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 54.7% |
| Value at Risk 5%th | 74.3% |
| Relative Tail Risk | -17.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.56 |
| Alpha | -38.06 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.436 |
| Beta | 0.827 |
| Beta Downside | 1.301 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.32% |
| Mean DD | 39.21% |
| Median DD | 42.00% |
Description: JYNT The Joint October 29, 2025
The Joint Corp. (NASDAQ:JYNT) is a franchisor of chiropractic clinics across the United States. Incorporated in 2010 and based in Scottsdale, Arizona, the company operates a network of locations that deliver musculoskeletal care under a franchise model, positioning itself within the Health Care Facilities sub-industry.
As of the latest filings, JYNT reports roughly 120 franchised clinics generating annual revenue in the $70-$80 million range, with same-store sales growth of approximately 6 % year-over-year-outpacing the broader outpatient services sector, which is expanding at roughly 3 % CAGR driven by an aging population and rising consumer interest in non-pharmaceutical pain management. Additionally, the company’s franchise fee structure yields a recurring royalty stream that currently contributes about 20 % of total earnings, providing a relatively insulated cash flow profile amid macro-economic fluctuations.
For a deeper quantitative breakdown of JYNT’s valuation metrics, the ValueRay platform offers a useful toolkit.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-799.1k TTM) > 0 and > 6% of Revenue (6% = 86.6k TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -5.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1824 % (prev 19.72%; Δ 1805 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 3.07m > Net Income -799.1k (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.4m) change vs 12m ago 1.72% (target <= -2.0% for YES) |
| Gross Margin -700.4% (prev 86.90%; Δ -787.3pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.94% (prev 107.5%; Δ -105.6pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.54 (EBITDA TTM -1.43m / Interest Expense TTM -6.01m) >= 6 (WARN >= 3) |
Altman Z'' 0.41
| (A) 0.38 = (Total Current Assets 59.4m - Total Current Liabilities 33.0m) / Total Assets 69.4m |
| (B) -0.37 = Retained Earnings (Balance) -25.8m / Total Assets 69.4m |
| (C) -0.04 = EBIT TTM -3.26m / Avg Total Assets 74.5m |
| (D) -0.55 = Book Value of Equity -25.8m / Total Liabilities 46.7m |
| Total Rating: 0.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.56
| 1. Piotroski 2.0pt |
| 2. FCF Yield 1.59% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.09 |
| 5. Debt/Ebitda 19.97 |
| 6. ROIC - WACC (= -23.94)% |
| 7. RoE -3.70% |
| 8. Rev. Trend -34.83% |
| 9. EPS Trend -10.00% |
What is the price of JYNT shares?
As of December 14, 2025, the stock is trading at USD 8.71 with a total of 163,624 shares traded.
Over the past week, the price has changed by +2.83%, over one month by +4.31%, over three months by -13.42% and over the past year by -21.25%.
Over the past week, the price has changed by +2.83%, over one month by +4.31%, over three months by -13.42% and over the past year by -21.25%.
Is JYNT a buy, sell or hold?
The Joint has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy JYNT.
- Strong Buy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JYNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.8 | 23.4% |
| Analysts Target Price | 10.8 | 23.4% |
| ValueRay Target Price | 7.5 | -13.8% |
JYNT Fundamental Data Overview December 10, 2025
Market Cap USD = 131.2m (131.2m USD * 1.0 USD.USD)
P/E Forward = 11.6279
P/S = 2.4223
P/B = 5.5478
P/EG = -0.7
Beta = 1.305
Revenue TTM = 1.44m USD
EBIT TTM = -3.26m USD
EBITDA TTM = -1.43m USD
Long Term Debt = 2.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 191.6k USD (from shortTermDebt, last quarter)
Debt = 2.09m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.6m USD (from netDebt column, last quarter)
Enterprise Value = 102.6m USD (131.2m + Debt 2.09m - CCE 30.7m)
Interest Coverage Ratio = -0.54 (Ebit TTM -3.26m / Interest Expense TTM -6.01m)
FCF Yield = 1.59% (FCF TTM 1.63m / Enterprise Value 102.6m)
FCF Margin = 113.1% (FCF TTM 1.63m / Revenue TTM 1.44m)
Net Margin = -55.34% (Net Income TTM -799.1k / Revenue TTM 1.44m)
Gross Margin = -700.4% ((Revenue TTM 1.44m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Gross Margin QoQ = 80.11% (prev 79.11%)
Tobins Q-Ratio = 1.48 (Enterprise Value 102.6m / Total Assets 69.4m)
Interest Expense / Debt = 175.5% (Interest Expense 3.67m / Debt 2.09m)
Taxrate = 3.44% (10.3k / 300.7k)
NOPAT = -3.15m (EBIT -3.26m * (1 - 3.44%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 59.4m / Total Current Liabilities 33.0m)
Debt / Equity = 0.09 (Debt 2.09m / totalStockholderEquity, last quarter 22.7m)
Debt / EBITDA = 19.97 (negative EBITDA) (Net Debt -28.6m / EBITDA -1.43m)
Debt / FCF = -17.53 (Net Debt -28.6m / FCF TTM 1.63m)
Total Stockholder Equity = 21.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.15% (Net Income -799.1k / Total Assets 69.4m)
RoE = -3.70% (Net Income TTM -799.1k / Total Stockholder Equity 21.6m)
RoCE = -13.74% (EBIT -3.26m / Capital Employed (Equity 21.6m + L.T.Debt 2.09m))
RoIC = -15.03% (negative operating profit) (NOPAT -3.15m / Invested Capital 20.9m)
WACC = 8.92% (E(131.2m)/V(133.3m) * Re(9.06%) + (debt cost/tax rate unavailable))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.16%
[DCF Debug] Terminal Value 65.99% ; FCFE base≈3.62m ; Y1≈2.38m ; Y5≈1.09m
Fair Price DCF = 1.22 (DCF Value 18.1m / Shares Outstanding 14.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -10.00 | EPS CAGR: 61.25% | SUE: 0.14 | # QB: 0
Revenue Correlation: -34.83 | Revenue CAGR: -12.53% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.05 | Chg30d=+0.013 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=0.37 | Chg30d=+0.008 | Revisions Net=-1 | Growth EPS=+1230.8% | Growth Revenue=+7.3%
P/E Forward = 11.6279
P/S = 2.4223
P/B = 5.5478
P/EG = -0.7
Beta = 1.305
Revenue TTM = 1.44m USD
EBIT TTM = -3.26m USD
EBITDA TTM = -1.43m USD
Long Term Debt = 2.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 191.6k USD (from shortTermDebt, last quarter)
Debt = 2.09m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.6m USD (from netDebt column, last quarter)
Enterprise Value = 102.6m USD (131.2m + Debt 2.09m - CCE 30.7m)
Interest Coverage Ratio = -0.54 (Ebit TTM -3.26m / Interest Expense TTM -6.01m)
FCF Yield = 1.59% (FCF TTM 1.63m / Enterprise Value 102.6m)
FCF Margin = 113.1% (FCF TTM 1.63m / Revenue TTM 1.44m)
Net Margin = -55.34% (Net Income TTM -799.1k / Revenue TTM 1.44m)
Gross Margin = -700.4% ((Revenue TTM 1.44m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Gross Margin QoQ = 80.11% (prev 79.11%)
Tobins Q-Ratio = 1.48 (Enterprise Value 102.6m / Total Assets 69.4m)
Interest Expense / Debt = 175.5% (Interest Expense 3.67m / Debt 2.09m)
Taxrate = 3.44% (10.3k / 300.7k)
NOPAT = -3.15m (EBIT -3.26m * (1 - 3.44%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 59.4m / Total Current Liabilities 33.0m)
Debt / Equity = 0.09 (Debt 2.09m / totalStockholderEquity, last quarter 22.7m)
Debt / EBITDA = 19.97 (negative EBITDA) (Net Debt -28.6m / EBITDA -1.43m)
Debt / FCF = -17.53 (Net Debt -28.6m / FCF TTM 1.63m)
Total Stockholder Equity = 21.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.15% (Net Income -799.1k / Total Assets 69.4m)
RoE = -3.70% (Net Income TTM -799.1k / Total Stockholder Equity 21.6m)
RoCE = -13.74% (EBIT -3.26m / Capital Employed (Equity 21.6m + L.T.Debt 2.09m))
RoIC = -15.03% (negative operating profit) (NOPAT -3.15m / Invested Capital 20.9m)
WACC = 8.92% (E(131.2m)/V(133.3m) * Re(9.06%) + (debt cost/tax rate unavailable))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.16%
[DCF Debug] Terminal Value 65.99% ; FCFE base≈3.62m ; Y1≈2.38m ; Y5≈1.09m
Fair Price DCF = 1.22 (DCF Value 18.1m / Shares Outstanding 14.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -10.00 | EPS CAGR: 61.25% | SUE: 0.14 | # QB: 0
Revenue Correlation: -34.83 | Revenue CAGR: -12.53% | SUE: 0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.05 | Chg30d=+0.013 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=0.37 | Chg30d=+0.008 | Revisions Net=-1 | Growth EPS=+1230.8% | Growth Revenue=+7.3%
Additional Sources for JYNT Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle